S&P 500   3,329.90 (+0.27%)
DOW   29,227.41 (+0.11%)
QQQ   224.76 (+0.66%)
AAPL   318.52 (+0.62%)
FB   222.06 (+0.28%)
MSFT   166.55 (+0.03%)
GOOGL   1,489.57 (+0.49%)
AMZN   1,889.93 (-0.11%)
CGC   24.44 (+1.20%)
NVDA   252.97 (+2.03%)
BABA   223.16 (+0.40%)
MU   59.91 (+1.59%)
GE   11.52 (-1.20%)
TSLA   591.19 (+8.04%)
AMD   51.70 (+1.27%)
T   39.12 (+1.53%)
F   9.21 (-0.11%)
NFLX   331.11 (-2.07%)
GILD   63.08 (+0.72%)
S&P 500   3,329.90 (+0.27%)
DOW   29,227.41 (+0.11%)
QQQ   224.76 (+0.66%)
AAPL   318.52 (+0.62%)
FB   222.06 (+0.28%)
MSFT   166.55 (+0.03%)
GOOGL   1,489.57 (+0.49%)
AMZN   1,889.93 (-0.11%)
CGC   24.44 (+1.20%)
NVDA   252.97 (+2.03%)
BABA   223.16 (+0.40%)
MU   59.91 (+1.59%)
GE   11.52 (-1.20%)
TSLA   591.19 (+8.04%)
AMD   51.70 (+1.27%)
T   39.12 (+1.53%)
F   9.21 (-0.11%)
NFLX   331.11 (-2.07%)
GILD   63.08 (+0.72%)
S&P 500   3,329.90 (+0.27%)
DOW   29,227.41 (+0.11%)
QQQ   224.76 (+0.66%)
AAPL   318.52 (+0.62%)
FB   222.06 (+0.28%)
MSFT   166.55 (+0.03%)
GOOGL   1,489.57 (+0.49%)
AMZN   1,889.93 (-0.11%)
CGC   24.44 (+1.20%)
NVDA   252.97 (+2.03%)
BABA   223.16 (+0.40%)
MU   59.91 (+1.59%)
GE   11.52 (-1.20%)
TSLA   591.19 (+8.04%)
AMD   51.70 (+1.27%)
T   39.12 (+1.53%)
F   9.21 (-0.11%)
NFLX   331.11 (-2.07%)
GILD   63.08 (+0.72%)
S&P 500   3,329.90 (+0.27%)
DOW   29,227.41 (+0.11%)
QQQ   224.76 (+0.66%)
AAPL   318.52 (+0.62%)
FB   222.06 (+0.28%)
MSFT   166.55 (+0.03%)
GOOGL   1,489.57 (+0.49%)
AMZN   1,889.93 (-0.11%)
CGC   24.44 (+1.20%)
NVDA   252.97 (+2.03%)
BABA   223.16 (+0.40%)
MU   59.91 (+1.59%)
GE   11.52 (-1.20%)
TSLA   591.19 (+8.04%)
AMD   51.70 (+1.27%)
T   39.12 (+1.53%)
F   9.21 (-0.11%)
NFLX   331.11 (-2.07%)
GILD   63.08 (+0.72%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NYSE:SXT - Sensient Technologies Stock Price, Forecast & News

$63.84
-0.29 (-0.45 %)
(As of 01/22/2020 11:38 AM ET)
Today's Range
$63.74
Now: $63.84
$64.36
50-Day Range
$63.05
MA: $64.50
$66.09
52-Week Range
$58.35
Now: $63.84
$75.21
Volume1,065 shs
Average Volume158,465 shs
Market Capitalization$2.70 billion
P/E Ratio20.46
Dividend Yield2.40%
Beta0.96
Sensient Technologies Corporation, together with its subsidiaries, develops, manufactures, and markets colors, flavors, and fragrances in North America, Europe, the Asia Pacific, and internationally. It operates through three segments: Flavors & Fragrances Group, Color Group, and Asia Pacific Group. The company offers flavor-delivery systems, and compounded and blended products; ingredient products, such as essential oils, natural and synthetic flavors, natural extracts, and aroma chemicals; fragrance products; and chili powder, paprika, and chili pepper, as well as dehydrated vegetables comprising parsley, celery, and spinach to the food, beverage, personal care, and household-products industries. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
CUSIP81725T10
Phone414-271-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.39 billion
Cash Flow$4.73 per share
Book Value$20.34 per share

Profitability

Net Income$157.36 million

Miscellaneous

Employees4,113
Market Cap$2.70 billion
Next Earnings Date2/14/2020 (Confirmed)
OptionableOptionable

Receive SXT News and Ratings via Email

Sign-up to receive the latest news and ratings for SXT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Sensient Technologies (NYSE:SXT) Frequently Asked Questions

What is Sensient Technologies' stock symbol?

Sensient Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SXT."

How often does Sensient Technologies pay dividends? What is the dividend yield for Sensient Technologies?

Sensient Technologies declared a quarterly dividend on Thursday, October 17th. Shareholders of record on Monday, November 4th will be given a dividend of $0.39 per share on Monday, December 2nd. This represents a $1.56 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Friday, November 1st. This is a positive change from Sensient Technologies's previous quarterly dividend of $0.36. View Sensient Technologies' Dividend History.

How were Sensient Technologies' earnings last quarter?

Sensient Technologies Co. (NYSE:SXT) issued its quarterly earnings results on Friday, October, 18th. The specialty chemicals company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by $0.02. The specialty chemicals company had revenue of $317.70 million for the quarter, compared to the consensus estimate of $344.11 million. Sensient Technologies had a return on equity of 14.98% and a net margin of 9.92%. The firm's quarterly revenue was down 7.3% compared to the same quarter last year. During the same period last year, the firm posted $0.95 earnings per share. View Sensient Technologies' Earnings History.

When is Sensient Technologies' next earnings date?

Sensient Technologies is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for Sensient Technologies.

What is the consensus analysts' recommendation for Sensient Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensient Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sensient Technologies.

Has Sensient Technologies been receiving favorable news coverage?

Media coverage about SXT stock has trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sensient Technologies earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Sensient Technologies.

Who are some of Sensient Technologies' key competitors?

What other stocks do shareholders of Sensient Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensient Technologies investors own include Verizon Communications (VZ), Walmart (WMT), Exxon Mobil (XOM), PepsiCo (PEP), Starbucks (SBUX), Walgreens Boots Alliance (WBA), Johnson & Johnson (JNJ), Marathon Petroleum (MPC), Philip Morris International (PM) and Target (TGT).

Who are Sensient Technologies' key executives?

Sensient Technologies' management team includes the folowing people:
  • Mr. Paul Manning, Chairman, CEO & Pres (Age 44)
  • Mr. Stephen J. Rolfs, Sr. VP & CFO (Age 54)
  • Mr. John J. Manning, VP, Gen. Counsel & Sec. (Age 50)
  • Ms. Amy Schmidt Jones, VP of HR & Sr. Counsel (Age 49)
  • Mr. Michael C. Geraghty, Pres of Color Group (Age 57)

Who are Sensient Technologies' major shareholders?

Sensient Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (0.79%), Tributary Capital Management LLC (0.68%), First National Bank of Omaha (0.06%), Nisa Investment Advisors LLC (0.02%), Diversified Trust Co (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Sensient Technologies stock include Gebhardt Deborah Mckeithan, Hank Brown and Thierry Hoang. View Institutional Ownership Trends for Sensient Technologies.

Which major investors are selling Sensient Technologies stock?

SXT stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue and Janney Montgomery Scott LLC. View Insider Buying and Selling for Sensient Technologies.

Which major investors are buying Sensient Technologies stock?

SXT stock was acquired by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, First National Bank of Omaha, Diversified Trust Co and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Sensient Technologies.

How do I buy shares of Sensient Technologies?

Shares of SXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sensient Technologies' stock price today?

One share of SXT stock can currently be purchased for approximately $63.93.

How big of a company is Sensient Technologies?

Sensient Technologies has a market capitalization of $2.71 billion and generates $1.39 billion in revenue each year. The specialty chemicals company earns $157.36 million in net income (profit) each year or $3.55 on an earnings per share basis. Sensient Technologies employs 4,113 workers across the globe.View Additional Information About Sensient Technologies.

What is Sensient Technologies' official website?

The official website for Sensient Technologies is http://www.sensient.com/.

How can I contact Sensient Technologies?

Sensient Technologies' mailing address is 777 EAST WISCONSIN AVENUE, MILWAUKEE WI, 53202. The specialty chemicals company can be reached via phone at 414-271-6755.


MarketBeat Community Rating for Sensient Technologies (NYSE SXT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  598
MarketBeat's community ratings are surveys of what our community members think about Sensient Technologies and other stocks. Vote "Outperform" if you believe SXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SXT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel